Home  ›  Peptides  ›  Retatrutide
Weight Loss · Metabolic · Liver

Retatrutide: The Triple-Agonist, Explained

It's the most closely watched drug in the obesity field — a once-weekly injectable posting weight-loss numbers no earlier drug has matched. Here's what the trials actually show, and the honest caveats that come with a drug still in testing.

By Steve Main · Vitality and Wellness

Our Retatrutide card gives the headline: a triple-hormone agonist from Eli Lilly that goes a step beyond Ozempic and Mounjaro. This guide unpacks how the "triple" mechanism works, walks through the striking Phase 2 and Phase 3 numbers, and — just as importantly — stays honest about what's still unknown. Because for all the excitement, retatrutide is not approved by any regulator as of 2026, and how you'd obtain it matters enormously.

Key Takeaways
  • Retatrutide hits three receptors at once — GLP-1, GIP, and glucagon — which is the leading explanation for its record weight-loss numbers.
  • Phase 2 showed up to ~24% average body-weight loss at 48 weeks; Phase 3 TRIUMPH trials have pushed higher still, with big drops in liver fat, blood sugar, and blood pressure.
  • It's still investigational — not FDA- or EMA-approved — so it isn't legally available as a finished, quality-controlled prescription product yet.
  • The single biggest safety message: do not buy "retatrutide" from unregulated research-chemical vendors. Purity and dosing are unverified and the risks are real.

What "triple agonist" actually means

The GLP-1 drugs you've heard of work by mimicking gut hormones that curb appetite and improve blood sugar. Semaglutide (Ozempic/Wegovy) activates one receptor: GLP-1. Tirzepatide (Mounjaro/Zepbound) activates two: GLP-1 and GIP. Retatrutide activates three — GLP-1, GIP, and glucagon.

That third receptor is the twist. We usually think of glucagon as the hormone that raises blood sugar, so adding it to a diabetes/obesity drug sounds backwards. But at the right balance, glucagon-receptor activation increases energy expenditure and pushes the body to burn stored fat — especially in the liver. So instead of relying on appetite suppression alone, retatrutide adds a metabolic "burn" lever. That's the leading theory for why its weight-loss numbers ran higher than the one- and two-receptor drugs, and why its liver-fat results were so dramatic.[1]

What the trials show

Phase 2: the numbers that turned heads

In the Phase 2 trial published in the New England Journal of Medicine, adults with obesity lost up to a mean of 24.2% of their body weight at 48 weeks on the 12 mg dose — roughly 58 pounds, exceeding what earlier GLP-1 drugs achieved. Nearly everyone responded: essentially all participants on higher doses lost at least 5% of their weight, and most crossed the 15% mark.[1]

Liver fat

A Phase 2 substudy in people with metabolic-associated fatty liver disease (MASLD) found up to a ~82% relative reduction in liver fat, with most patients clearing measurable steatosis ("fatty liver") entirely at the higher doses.[2] That's a striking result for a condition with few good drug options — and it ties directly back to the glucagon mechanism.

Phase 3: the TRIUMPH program

The larger, longer Phase 3 trials have continued the trend. Lilly's TRIUMPH-1 topline reported up to 28.3% average weight loss at 80 weeks (around 30% in higher-BMI patients continued further), alongside meaningful drops in systolic blood pressure.[3] In type 2 diabetes, the TRANSCEND-T2D-1 trial reported up to a 2.0% reduction in A1C, with as many as 90% of patients reaching the standard A1C goal.[4] And TRIUMPH-4 reported large weight loss paired with major improvements in knee osteoarthritis pain and obstructive sleep apnea severity.[5]

Put together, retatrutide isn't just moving the scale — the trials show it improving the whole cluster of problems that ride along with excess weight.
How It's Used In Trials A once-weekly subcutaneous injection, slowly escalated from a low starting dose (around 0.5–2 mg) up to a target of 4, 8, or 12 mg over several months. That gradual ramp exists specifically to limit nausea. This is a physician-run prescription protocol — the dosing figures here explain the research, not a how-to. Rapid weight loss can also cost muscle, so adequate protein and resistance training matter alongside any GLP-class drug.
Safety & The Sourcing Problem Gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) are the most common, mostly mild-to-moderate and concentrated in the dose-escalation phase — nausea reached ~60% at the 12 mg dose. Heart rate rose about 5–10 bpm on average, and discontinuation from side effects climbed with dose. Long-term safety is still being established in Phase 3. Most important: because retatrutide is not yet approved, it isn't available as a finished pharmacy product — and "retatrutide" sold by online research-chemical vendors is unregulated, of unverified purity and dose, and genuinely dangerous. This is not a compound to self-source.

The honest status

Retatrutide is arguably the most promising obesity drug in development — but "in development" is the operative phrase. As of 2026 it is not approved by the FDA, EMA, or any regulator, which means the safety and efficacy picture is still being finalized and it cannot be legally prescribed as an approved treatment yet. If and when it clears Phase 3 and earns approval, it would become available the right way: as a quality-controlled prescription, under medical supervision. Until then, the trial data is worth understanding — and worth waiting for.

Selected Research

  1. Jastreboff et al., New England Journal of Medicine, 2023 — Phase 2 trial: retatrutide produced up to 24.2% mean weight reduction at 48 weeks in adults with obesity. Randomized, double-blind, placebo-controlled. NEJM
  2. Sanyal et al., Nature Medicine, 2024 — Phase 2a MASLD substudy: up to ~82% relative reduction in liver fat, with resolution of steatosis in most patients at the highest doses. Nature Medicine
  3. Eli Lilly, TRIUMPH-1 Phase 3 topline results, May 2026 — up to 28.3% average weight loss and lower systolic blood pressure at 80 weeks; investigational, not yet FDA-approved. Lilly
  4. Eli Lilly, TRANSCEND-T2D-1 Phase 3 results, 2025 — up to 2.0% A1C reduction in type 2 diabetes, with up to 90% of patients reaching an A1C below 7%. PR Newswire
  5. Eli Lilly, TRIUMPH-4 Phase 3 results, Dec 2025 — large weight loss with marked reductions in knee osteoarthritis pain and obstructive sleep apnea severity. PR Newswire

Retatrutide is an investigational drug under Phase 3 evaluation and is not approved by the FDA or EMA as of 2026. Cited for education only — not medical advice, a recommendation, or a guarantee of results. Individual responses and risks vary.

Explore the rest of the Peptide Guides

Retatrutide is one of the compounds we break down honestly — what the research shows, why it matters, and the safety realities.

← Back to Peptide Guides ▶ Subscribe on YouTube